

Giuseppe Gargiulo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9286137/publications.pdf>

Version: 2024-02-01

122
papers

4,682
citations

109137

35
h-index

106150

65
g-index

127
all docs

127
docs citations

127
times ranked

6461
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Inhibition with Ticagrelor 60Âmg Versus 90Âmg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 1031-1038.	1.3	3
2	Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 495-498.	1.0	5
3	The Effects of Cangrelor on Platelet Aggregation in STEMI Patients. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 229-230.	1.1	0
4	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
5	Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. <i>Global & Regional Health Technology Assessment</i> , 2022, 9, 17-26.	0.2	0
6	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: a Multicenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial Infarction Referred for PrimAry Percutaneous InTERvention (FABOLUS FASTER) Trial: Design and Rationale. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 110-119.	1.1	7
7	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2021, 42, 308-319.	1.0	90
8	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	1.4	24
9	Consolidating the value of the standardised ARC-HBR definition. <i>EuroIntervention</i> , 2021, 16, 1126-1128.	1.4	6
10	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronaryâ€Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 375-388.	1.2	70
11	Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2021, 16, e1245-e1253.	1.4	5
12	Response by Gargiulo et al to Letter Regarding Article, â€Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segmentâ€Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trialâ€ Circulation, 2021, 143, e797-e798.	1.6	0
13	Sexâ€Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	1.6	23
14	Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 950-961.	1.5	10
15	Aspirin Monotherapy After BioFreedom Stent and 1-Month DAPT. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1812-1814.	1.1	0
16	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1170-1179.	0.4	4
17	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.	1.4	45
18	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e29-e30.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. <i>EuroIntervention</i> , 2021, 17, e971-e980.	1.4	13
20	Complete Revascularization in Acute and Chronic Coronary Syndrome. <i>Cardiology Clinics</i> , 2020, 38, 491-505.	0.9	4
21	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.	1.0	89
22	Lugar de acceso y tipo de anticoagulante en pacientes con síndrome coronario agudo en clase Killip avanzada o con parada cardíaca extrahospitalaria. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 893-901.	0.6	5
23	Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 660-666.	0.6	10
24	Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. <i>Cardiovascular Diabetology</i> , 2020, 19, 76.	2.7	75
25	Antithrombotic treatment strategies after PCI – Authors' reply. <i>Lancet, The</i> , 2020, 395, 867-868.	6.3	0
26	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 893-901.	0.4	7
27	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. <i>Circulation</i> , 2020, 142, 441-454.	1.6	67
28	Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. <i>European Heart Journal</i> , 2020, 41, 1701-1702.	1.0	3
29	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , 2020, 16, 371-379.	1.4	132
30	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal</i> , 2019, 40, 3757-3767.	1.0	211
31	Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2116-2118.	1.1	6
32	EKG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.	0.4	7
33	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. <i>Lancet, The</i> , 2019, 394, 1335-1343.	6.3	465
34	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 810-822.	2.2	18
35	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 758-774.	1.2	22
36	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , 2019, 277, 60-65.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. <i>EuroIntervention</i> , 2019, 15, e269-e278.	1.4	2
38	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. <i>International Journal of Cardiology</i> , 2018, 260, 42-46.	0.8	11
39	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. <i>American Journal of Cardiology</i> , 2018, 122, 6-11.	0.7	13
40	To EncourAGE Individualized Dual Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 444-447.	1.1	5
41	<i>AKAP1</i> Regulates Vascular Function and Endothelial Cells Behavior. <i>Hypertension</i> , 2018, 71, 507-517.	1.3	33
42	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 36-50.	1.1	47
43	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1231-1242.	1.2	32
44	Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1046-1049.	1.1	4
45	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , 2018, 392, 940-949.	6.3	555
46	Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2017, 19, 2.	1.3	4
47	Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E73-E84.	0.7	18
48	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. <i>Annals of Internal Medicine</i> , 2017, 166, 606.	2.0	1
49	Response by Valgimigli and Gargiulo to Letter Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?" <i>Circulation</i> , 2017, 135, e1037-e1038.	1.6	0
50	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	63
51	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	1.2	132
52	DAPT Duration After Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1211-1214.	1.1	3
53	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , 2017, 167, 17.	2.0	56
54	Deciding on the Duration of Dual Antiplatelet Therapy "When the Choice Between 2 Evils Is Still Evil. <i>JAMA Cardiology</i> , 2017, 2, 488.	3.0	3

#	ARTICLE	IF	CITATIONS
55	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2017, 120, 2025-2030.	0.7	18
56	Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. <i>European Heart Journal</i> , 2017, 38, 2948-2956.	1.0	383
57	Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study. <i>Cardiovascular Diabetology</i> , 2017, 16, 7.	2.7	7
58	Meta-Analysis of Effect of Body Mass Index on Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2017, 119, 308-316.	0.7	37
59	Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	0
60	Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S102-S106.	0.7	1
61	Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. <i>Journal of Thoracic Disease</i> , 2017, 9, 4260-4265.	0.6	9
62	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. <i>EuroIntervention</i> , 2017, 13, 78-86.	1.4	21
63	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives. <i>EuroIntervention</i> , 2017, 13, 717-733.	1.4	37
64	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 843-849.	0.6	9
65	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
66	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. <i>Annals of Internal Medicine</i> , 2016, 165, 334.	2.0	102
67	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 976-977.	1.1	0
68	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 253-262.	0.4	66
69	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. <i>International Journal of Cardiology</i> , 2016, 203, 264-266.	0.8	24
70	Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 721-724.	0.4	0
71	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. <i>American Journal of Cardiology</i> , 2016, 118, 1888-1896.	0.7	37
72	Bivalirudina frente a heparina no fraccionada en síndromes coronarios agudos: ¿hay un vencedor?. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 721-724.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. <i>International Journal of Cardiology</i> , 2016, 221, 695-696.	0.8	2
74	Bivalirudin in Current Practice. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1321-1323.	1.1	5
75	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. <i>JAMA Cardiology</i> , 2016, 1, 795.	3.0	68
76	Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1780-1789.	1.1	23
77	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2280-2288.	1.1	26
78	Renal dysfunction and transcatheter aortic valve implantation outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1315-1323.	0.6	11
79	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. <i>BMJ, The</i> , 2016, 355, i5483.	3.0	48
80	Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 524-529.	0.6	17
81	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 475-486.	0.4	15
82	Developing drugs for use before, during and soon after percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 803-818.	0.9	14
83	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. <i>American Heart Journal</i> , 2016, 174, 95-102.	1.2	53
84	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 210-211.	2.3	5
85	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. <i>EuroIntervention</i> , 2016, 12, e152-e159.	1.4	7
86	A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2016, 12, e1047-e1056.	1.4	80
87	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1150-1161.	0.7	32
88	Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes. <i>Frontiers in Cardiovascular Medicine</i> , 2015, 2, 13.	1.1	6
89	New Cerebral Lesions at Magnetic Resonance Imaging after Carotid Artery Stenting Versus Endarterectomy: An Updated Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0129209.	1.1	32
90	Radial versus femoral access for cardiac catheterisation – Authors' reply. <i>Lancet, The</i> , 2015, 386, 2394.	6.3	10

#	ARTICLE	IF	CITATIONS
91	Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002220.	1.4	73
92	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 518-527.	0.7	75
93	Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with left main coronary artery disease: An updated meta-analysis of randomized trials and adjusted observational studies. <i>International Journal of Cardiology</i> , 2015, 195, 79-81.	0.8	22
94	Cyphering the Mechanism of Late Failure of Bioresorbable Vascular Scaffolds in Percutaneous Coronary Intervention of the Left Main Coronary Artery. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e95-e97.	1.1	1
95	Early discharge after transfemoral transcatheter aortic valve implantation. <i>Heart</i> , 2015, 101, 1485-1490.	1.2	80
96	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1205.e5-1205.e6.	0.8	0
97	Prevalence and characteristics of true and apparent treatment resistant hypertension in the Campania Salute Network. <i>International Journal of Cardiology</i> , 2015, 184, 417-419.	0.8	6
98	New-Onset Coronary Aneurism and Late-Acquired Incomplete Scaffold Apposition After Full Polymer Jacket of Chronic Total Occlusion With Bioresorbable Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e41-e43.	1.1	9
99	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2015, 189, 77-78.	0.8	5
100	Embolic protection devices during carotid artery stenting: Is there a difference between proximal occlusion and distal filter?. <i>International Journal of Cardiology</i> , 2015, 187, 592-593.	0.8	3
101	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1639-1640.	1.2	32
102	Dermcidin: a skeletal muscle myokine modulating cardiomyocyte survival and infarct size after coronary artery ligation. <i>Cardiovascular Research</i> , 2015, 107, 431-441.	1.8	27
103	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. <i>BMJ, The</i> , 2015, 351, h5392.	3.0	102
104	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2015, 11, 690-697.	1.4	48
105	Antithrombotic therapy in TAVI patients: changing concepts. <i>EuroIntervention</i> , 2015, 14, W92-W95.	1.4	23
106	Time for science to catch up with clinical practice?. <i>Journal of Thoracic Disease</i> , 2015, 7, E603-6.	0.6	2
107	Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome. <i>Reviews in Cardiovascular Medicine</i> , 2015, 16, 131-139.	0.5	0
108	Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. <i>Current Vascular Pharmacology</i> , 2014, 12, 106-116.	0.8	26

#	ARTICLE	IF	CITATIONS
109	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2014, 12, 1185-1203.	0.6	23
110	Cerebral Embolic Lesions Detected With Diffusion-Weighted Magnetic Resonance Imaging Following Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2014, 7, 1177-1183.	1.1	80
111	Increased mortality after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and low ejection fraction: A meta-analysis of 6898 patients. International Journal of Cardiology, 2014, 176, 32-39.	0.8	54
112	Meta-Analysis of Mortality Outcomes and Mitral Regurgitation Evolution in 4,839 Patients Having Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. American Journal of Cardiology, 2014, 114, 875-882.	0.7	60
113	Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. International Journal of Cardiology, 2013, 167, 2566-2571.	0.8	27
114	Genetic Deletion of Uncoupling Protein 3 Exaggerates Apoptotic Cell Death in the Ischemic Heart Leading to Heart Failure. Journal of the American Heart Association, 2013, 2, e000086.	1.6	50
115	Unexpected preserved brain perfusion imaging despite severe and diffuse atherosclerosis of supra-aortic trunks : case report - online article. Cardiovascular Journal of Africa, 2013, 24, e12-e14.	0.2	4
116	Use of statins in lower extremity artery disease: a review. BMC Surgery, 2012, 12, S15.	0.6	17
117	Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication. BMC Surgery, 2012, 12, S19.	0.6	11
118	Balancing hemorrhagic and thrombotic complications in a patient with a very late paclitaxel-eluting stent thrombosis: a clinical case report. Journal of Cardiovascular Medicine, 2011, 12, 366-369.	0.6	4
119	EGFR trans-activation by urotensin II receptor is mediated by β^2 -arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Research in Cardiology, 2011, 106, 577-589.	2.5	68
120	Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1983-H1989.	1.5	31
121	Induction of Mitogen-Activated Protein Kinases Is Proportional to the Amount of Pressure Overload. Hypertension, 2010, 55, 137-143.	1.3	24
122	A kinase anchor protein 121 regulates mitochondrial function and survival in cardiac and smooth muscle cells. Journal of Molecular and Cellular Cardiology, 2007, 42, S81-S82.	0.9	0